The Mectizan® Donation Program - Highlights from 2005

Filaria Journal

Volumn 5, Issue , 2006, Pages

  Alleman, Mary M ^a   Twum Danso, Nana A Y ^a   Thylefors, Björn I ^a  

^a Mectizan Donation Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; IVERMECTIN;

ADVISORY COMMITTEE; AFRICA; BRAIN TOXICITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; FILARIASIS; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; MORBIDITY; NEUROTOXICITY; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE CONTROL; PARASITE TRANSMISSION; PHARMACEUTICAL CARE; REVIEW; RISK BENEFIT ANALYSIS; SOUTH AND CENTRAL AMERICA; WUCHERERIA BANCROFTI; YEMEN;

EID: 33750388223     PISSN: 14752883     EISSN: 14752883     Source Type: Journal    
DOI: 10.1186/1475-2883-5-11     Document Type: Review

References (46)

1. Colatrella B: The Mectizan® Donation Programme-Successful collaboration between the public and private sectors. Essential Drugs Monitor 2003, 33:27-28.
2. World Health Organization: Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis (in countries where onchocerciasis is co-endemic). WHO/CDS/CPE/2000.16. Geneva World Health Organization 2000.
3. Ottesen EA, Duke BOL, Karam M, Behbehani K: Strategies and tools for the control/elimination of lymphatic filariasis. Bulletin of the World Health Organization 1997, 75:491-503.
4. Mectizan® Donation Program: Initial Application for Mectizan® and Albendazole for Progammes to Eliminate Lymphatic Filariasis and Control Onchocerciasis. Atlanta Mectizan® Donation Program 2005.
5. Agence française de sécurité sanitaire des produits de santé: Résumé des caractéristiques du produit (Mectizan). Saint-Denis Agence française de sécurité sanitaire des produits de santé 2005.
6. Ngoumou P, Walsh JF: A manual for rapid epidemiological mapping of onchocerciasis. TDR/TDE/ONCHO/93.4. Geneva World Health Organization 1993.
7. Boatin B, Molyneux DH, Hougard JM, Christensen OW, Alley ES, Yameogo L, Seketeli A, Dadzie KY: Patterns of epidemiology and control of onchocerciasis in West Africa. Journal of Helminthology 1997, 71:91-101.
8. Borsboom GJJM, Boatin BA, Nagelkerke NJD, Agoua H, Akpoboua KLB, Alley EWS, Bissan Y, Renz A, Yameogo L, Remme JHF, Habbema JDF: Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria Journal 2003, 2:8.
9. Kale O, Grunewald J, Koulischer G, Massougbodji A, Sachndeva P: Onchocerciasis Control Programme External Evaluation 2002. Ouagadougou African Programme for Onchocerciasis Control World Health Organization 2002.
10. World Health Organization: Onchocerciasis (river blindness) Report from the fifteenth InterAmerican Conference on Onchocerciasis, Caracas, Venezuela. Weekly Epidemiological Record 2006, 81:293-296.
11. Sékétéli A: APOC at mid-point: so far so good. Annals of Tropical Medicine and Parasitology 2002, 96(Supplement 1):3-4.
12. World Health Organization: Report of the Seventh Session of the Joint Action Forum of the African Programme for Onchocerciasis Control. Ouagadougou African Programme for Onchocerciasis Control World Health Organization 2001.
13. World Health Organization: Success in Africa: The Onchocerciasis Control Programme 16 West Africa, 1974-2002. Geneva World Health Organization 2002.
14. Richards FO, Boatin B, Sauerbrey M, Sékétéli A: Control of onchocerciasis today: status and challenges. Trends in Parasitology 2001, 17:558-563.
15. World Health Organization: Onchocerciasis Control in the Special Intervention Zones including Sierra Leone in the OCP area. Plan of Action and Budget. Ouagadougou Onchocerciasis Control Programme in West Africa World Health Organization 2002.
16. TDR (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases): Tropical disease research: progress 2003-Seventeenth Programme Report of the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases. TDR/GEN/05.1. Geneva World Health Organization 2005.
17. Blanks J, Richards F, Beltrán F, Collins R, Álvarez E, Zea Flores G, Bauler B, Cedillos R, Heisler M, Brandling-Bennett D, Baldwin W, Bayona M, Klein R, Jacox M: The Onchocerciasis Elimination Program for the Americas: a history of partnership. Pan American Journal of Public Health 1998, 3:367-374.
18. Boatin B, Richards FO: Control of Onchocerciasis. Advances in Parasitology 2006, 61:349-394.
19. World Health Organization: Criteria for certification of interruption of transmission/elimination of human onchocerciasis. WHO/CDS/CPE/CEE/ 2001.18a. Geneva World Health Organization 2001.
20. Büttner DW, Laer GV, Mannweiler E, Buttner M: Clinical, parasitological and serological studies on onchocerciasis in the Yemen Arab Republic. Tropenmedizin und Parasitologie 1982, 33:201-212.
21. World Health Organization: Report of a WHO Expert Committee on Onchocerciasis Control. WHO Technical Report Series No. 852. Geneva World Health Organization 1995.
22. Al-Qubati Y: The first use of ivermectin for the treatment of onchocerciasis in Yemen. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994, 88:343.
23. World Health Organization: WHO Expert Committee on Onchocerciasis. Third Report. WHO Technical Report Series No. 757. Geneva World Health Organization 1987.
24. Ottesen EA: Lymphatic Filariasis: Treatment, Control, and Elimination. Advances in Parasitology 2006, 61:395-441.
25. World Health Organization: Final Communique of the Fifth Session of the Joint Action Forum of the African Programme for Onchocerciasis Control. Ouagadougou African Programme for Onchocerciasis Control World Health Organization 1999.
26. Malecela-Lazaro M, Twum-Danso N: LF Research Forum, 2.4 Program implementation. The American Journal of Tropical Medicine and Hygiene 2004, 71:16-19.
27. Gyapong JO, Twum-Danso NAY: Global elimination of lymphatic filariasis: fact or fantasy? Tropical Medicine and International Health 2006, 11:125-128.
28. Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, Chippaux JP: Effets secondaires du traitement de la loase hypermicrofilarémique par l'ivermectine. Bulletin de la Société de Pathologie Exotique 1995, 88:105-112.
29. Chippaux JP, Boussinesq M, Gardon J, Gardon-Wendel N, Ernould JC: Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitology Today 1996, 12:448-450.
30. Boussinesq M, Gardon J, Kamgno J, Pion SDS, Gardon-Wendel N, Chippaux JP: Relationship between the prevalence and intensity of Loa loa infection in the Central province of Cameroon. Annals of Tropical Medicine and Parasitology 2001, 95:495-507.
31. Thomson MC, Obsomer V, Dunne M, Connor SJ, Molyneux DH: Satellite mapping of Loa loa prevalence in relation to ivermectin use in west and central Africa. The Lancet 2000, 356:1077-1078.
32. Takougang I, Meremikwu M, Wandji S, Yenshu EV, Aripko B, Lamlenn SB, Braide EL, Enyong P, Meli J, Kale O, Remme J: Rapid assessment method for prevalence and intensity of Loa loa infection. Bulletin of the World Health Organization 2002, 80:852-858.
33. Addis DG, Rheinghans R, Twum-Danso NAY, Richards F: A framework for decision-making for mass distribution of Mectizan® in areas endemic for Loa loa. Filaria Journal 2003,2(Supplement 1):S9.
34. Mectizan® Expert Committee/Technical Consultative Committee: Recommendations for the treatment of onchocerciasis with Mectizan® in areas co-endemic for onchocerciasis and loiasis. Atlanta Mectizan® Donation Program 2004.
35. Dunyo SK, Nkrumah FK, Simonson PE: Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000, 94:437-443.
36. Dreyer G, Noröes J, Figueredo-Silva J, Piessens WF: Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitology Today 2000, 16:544-548.
37. Addis DG, Mackenzie C: LF Research Forum, 2.3 LF disease-clinical management. The American Journal of Tropical Medicine and Hygiene 2004, 71:12-15.
38. Anonymous: Mass treatment of LF in loiasis endemic areas: A strategy to assess whether the addition of albendazole to ivermectin for the mass treatment of LF poses any additional risks in areas that are co-endemic with Loa loa, Summary of an informal consultation of experts. Geneva World Health Organization 2005.
39. World Health Organization: Sixth meeting of the Technical Advisory Group on the Global Elimination of Lymphatic Filariasis, Geneva, Switzerland, 20-23 September 2005. Weekly Epidemiological Record 2005, 80:401-408.
40. World Health Organization: Report on active surveillance for adverse events following the use of drug co-administrations in the Global Programme to Eliminate Lymphatic Filariasis. Weekly Epidemiological Record 2003, 78:313-320.
41. Fay M: Designing a study to test whether the addition of albendazole to ivermectin adds additional risk of SAEs in areas that are co-endemic with Loa loa or Onchocerca volvulus. Report submitted to WHO/TDR 2005.
42. World Health Organization: Final Communique of the Eleventh Session of the Joint Action Forum of the African Programme for Onchoceriasis Control. Ouagadougou African Programme for Onchocerciasis Control World Health Organization 2005.
43. Haselow N, Obadiah M, Akame J: The Integration of Vitamin A Supplementation into Community-Directed Treatment with Ivermectin: A Practical Guide for Africa. New York Helen Keller International 2004.
44. Micronutrient Initiative: The Micronutrient Initiative Annual Report 04/ 05. Ottawa The Micronutrient Initiative 2005.
45. Kabatereine NB, Tukahebwa E, Kazibwe F, Namwangye H, Zaramba S, Brooker S, Stothard JR, Kamenka C, Whawell S, Webster JP, Fenwick A: Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100:208-215.
46. Molyneux D: Onchocerciasis control and elimination: coming of age in resource-constrained health systems. Trends in Parasitology 2005, 21:525-529.